Last updated: November 7, 2026, 10:30 AM IST
On October 23, 2026, in Bunia, a city in the eastern Democratic Republic of the Congo, the first participants in a new vaccine trial rolled up their sleeves. The trial is called Tumaini — the Swahili word for hope — and it is the first vaccine trial ever run against Bundibugyo Ebola, a strain of the virus for which no approved vaccine exists.
That last fact is the whole story. Ebola is a word most people associate with a vaccine by now, because Ervebo, a licensed vaccine, exists for the more common Zaire strain. But Bundibugyo is a different species of the virus, and until Tumaini, nothing had ever been tested against it in a proper trial — even as the outbreak in the DRC grew into one of the largest on record. Tumaini is an attempt to close that gap while the outbreak is still happening, which is both the bravest and the hardest way to run a trial.
The numbers behind the urgency are stark. In its Disease Outbreak News update of October 23, the World Health Organization reported 9,704 confirmed cases and 4,687 deaths in the DRC as of October 20 — a case fatality ratio of about 48.3 percent. Nearly one in two confirmed patients had died. Those are the conditions under which Tumaini began, in Bunia, the capital of Ituri province and the epicentre of the outbreak.
Why Bundibugyo had no vaccine until now
Ebola is not one virus. It is a family of related viruses, and the differences between them matter more than most people realise. The Zaire species, the one behind the famous West African epidemic of 2014 to 2016 and several later outbreaks, has a licensed vaccine in Ervebo and a body of trial evidence behind it. Bundibugyo, first identified in Uganda in 2007, is a separate species. It causes the same terrifying disease — fever, bleeding, organ failure — but a vaccine designed for one species cannot simply be assumed to work against another.
That assumption is exactly what Tumaini is testing first, and the design is refreshingly honest about it. The trial opens by giving participants Ervebo, the licensed Zaire vaccine, to find out whether it offers any cross-protection against Bundibugyo at all. It is a sensible first step: Ervebo is available, its safety profile is known, and if it works even partially, it could save lives immediately. But nobody is pretending the answer is already known. Cross-protection is a hypothesis, not a promise, and the trial exists because the hypothesis needs evidence.
Behind Ervebo in the queue are two vaccines built specifically for Bundibugyo. One comes from the University of Oxford, using its ChAdOx1 platform, and the other is an mRNA candidate from Moderna, both supported by the Coalition for Epidemic Preparedness Innovations, known as CEPI, which funds the trial. They are expected to join Tumaini shortly, turning it into a platform trial — one shared framework that can test several candidates without starting from scratch each time. If either of them works, the DRC will have, for the first time, a vaccine designed for the virus actually circulating in its hospitals.
How a ring vaccination trial works
Tumaini uses ring vaccination, a method with a long and honourable history in outbreak control. When a confirmed case is found, the trial offers vaccination to that person's contacts, and then to the contacts of those contacts — a ring drawn around each case, designed to stop the chain of transmission where it is actually moving. The same approach helped end smallpox, and it was used with Ervebo during Ebola outbreaks in West Africa and later in the DRC.
There are two reasons to run a trial this way during an outbreak rather than waiting for peacetime. The first is ethical: in ring vaccination, the people most at risk get the vaccine first, rather than watching a trial happen somewhere safe while they remain exposed. The second is scientific: vaccinating around real cases is how you learn whether a vaccine prevents real infections, not just whether it produces antibodies in a laboratory. The trade-off is that it is operationally demanding — teams must move fast, trace contacts accurately, and keep careful records in places where roads, power and security cannot be taken for granted.
Tumaini also makes a deliberate point of including groups that trials have historically left out. Pregnant women and children aged 12 and over can take part, according to WHO and Al Jazeera's reporting. That matters because those groups are often among the most vulnerable in an outbreak, and because excluding them from trials means doctors end up guessing about safety and dosing when they need certainty most. It is a small detail in the trial protocol, and it says a lot about how seriously the organisers are taking the word 'hope' in the trial's name.
Who is running it, and what happens next
Tumaini is a DRC-led effort, co-led by the country's national biomedical research institute, the INRB, and the University of Antwerp, with the World Health Organization supporting it and CEPI funding it. That leadership matters. Too many outbreak responses in the past were run from outside, with local teams treated as helpers rather than owners. Here the structure is the other way round: Congolese researchers are in charge, international partners are supporting, and the WHO's role, in Director-General Tedros Adhanom Ghebreyesus's words, is to support 'this DRC-led effort to find answers and save lives'.
Tedros announced the start of the trial on X on October 23, writing: 'Science gives us hope. Today, in Bunia, DRC, the first participants were vaccinated in a new Ebola vaccine trial called Tumaini, which means hope in Swahili. This trial will help us understand whether any of the vaccine candidates designed for Bundibugyo virus work.' It is a careful sentence, and the care is the point. He did not say the trial will work. He said it will help us understand whether the candidates work — which is what a trial is for.
What happens next is a slow, unglamorous process that deserves more attention than it usually gets. Researchers will track safety first — any side effects, in any participant — and immune response second, and then, as cases accumulate in the rings, whether vaccinated contacts actually get infected less often than expected. There is no date by which Tumaini will deliver a verdict, and anyone who gives you one is guessing. The realistic expectation is months of careful follow-up, with the Oxford and Moderna candidates joining as their own earlier-stage testing allows. If the trial succeeds, the payoff is not just for this outbreak: it is a proven vaccine, and a proven trial platform, ready for the next time Bundibugyo appears.
What this does not mean — yet
It is worth being blunt about the limits, because outbreak news is where exaggeration does the most damage. Tumaini is not a vaccine rollout. Nobody in Bunia received a proven Bundibugyo vaccine on October 23, because no proven Bundibugyo vaccine exists yet. The first participants received Ervebo, a vaccine for a different species, as part of a test. That distinction is not pedantry; it is the difference between hope and a false promise, and the people of Ituri deserve the first without being sold the second.
Nor does the trial, on its own, end the outbreak. Vaccines work alongside the unglamorous basics: finding cases early, isolating patients safely, tracing contacts, burying the dead with dignity and without transmission, and keeping health workers — who have paid a terrible price in every Ebola outbreak — protected. Tumaini strengthens one part of that system. The rest of it still has to function, day after day, in one of the hardest places on earth to run a health system.
And there is a wider lesson that will outlive this outbreak. Bundibugyo went without a vaccine for nearly twenty years after it was first identified, not because the science was impossible but because the market for it was small and the patients were poor. CEPI exists precisely to fix that failure, funding vaccines for diseases the commercial market ignores. Tumaini is CEPI's model working as intended — late, but working. The question it leaves behind is how many other diseases are still waiting for their own Tumaini.
Frequently Asked Questions
What is the Tumaini trial?
Tumaini is a Phase 2/3 vaccine trial in the Democratic Republic of the Congo, the first ever against Bundibugyo Ebola. The first participants were vaccinated in Bunia, Ituri province, on October 23, 2026.
Why is Tumaini historic?
Because no approved vaccine exists for the Bundibugyo species of Ebola. Tumaini is the first trial designed to find one, testing Ervebo first for cross-protection and Bundibugyo-specific candidates from Oxford and Moderna afterwards.
What does Tumaini mean?
Hope, in Swahili. The name was chosen for the trial launched in the outbreak's epicentre, Bunia, in eastern DRC.
How does ring vaccination work?
When a confirmed case is found, vaccination is offered to the patient's contacts, and then to the contacts of those contacts — a ring around each case, meant to break chains of transmission.
How big is the DRC Ebola outbreak?
According to WHO's October 23 update, there were 9,704 confirmed cases and 4,687 deaths in the DRC as of October 20, 2026 — a case fatality ratio of about 48.3 percent.
Sources
- WHO / CEPI via MediaPavilion — Ebola vaccine trial begins in DR Congo
- Recatools — Tumaini Ebola vaccine trial begins in Bunia, DR Congo
- Nature World News — Bundibugyo Ebola cases near 10,000 as Congo starts first vaccine trial
My Personal Take
What stays with me about Tumaini is not the science, impressive as it is — it is the name. Calling a trial 'hope' in the middle of an outbreak that has killed more than 4,600 people is either brave or reckless, and I think it is brave, because the organisers have been careful not to oversell it. They did not announce a cure. They announced a test. That honesty is rarer than it should be in outbreak news.
My other thought is less comfortable: Bundibugyo was identified in 2007, and it took until 2026, and nearly 10,000 cases, for a trial to begin. That is not a failure of Congolese doctors, who have been fighting this virus with almost nothing. It is a failure of a system that only funds vaccines when the patients can pay. If Tumaini works, celebrate it — and then ask why it took so long, and which disease is next in the queue.
0 Comments